95 related articles for article (PubMed ID: 31412710)
1. Synergistic Effects of PI3K and c-Myc Co-targeting in Acute Leukemia: Shedding New Light on Resistance to Selective PI3K-δ Inhibitor CAL-101.
Riyahi N; Safaroghli-Azar A; Sheikh-Zeineddini N; Sayyadi M; Bashash D
Cancer Invest; 2019; 37(7):311-324. PubMed ID: 31412710
[TBL] [Abstract][Full Text] [Related]
2. Suppression of c-Myc using 10058-F4 exerts caspase-3-dependent apoptosis and intensifies the antileukemic effect of vincristine in pre-B acute lymphoblastic leukemia cells.
Sheikh-Zeineddini N; Bashash D; Safaroghli-Azar A; Riyahi N; Shabestari RM; Janzamin E; Safa M
J Cell Biochem; 2019 Aug; 120(8):14004-14016. PubMed ID: 30957273
[TBL] [Abstract][Full Text] [Related]
3. Small molecule inhibitor of c-Myc 10058-F4 inhibits proliferation and induces apoptosis in acute leukemia cells, irrespective of PTEN status.
Bashash D; Sayyadi M; Safaroghli-Azar A; Sheikh-Zeineddini N; Riyahi N; Momeny M
Int J Biochem Cell Biol; 2019 Mar; 108():7-16. PubMed ID: 30639430
[TBL] [Abstract][Full Text] [Related]
4. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
[TBL] [Abstract][Full Text] [Related]
5. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia.
Huang MJ; Cheng YC; Liu CR; Lin S; Liu HE
Exp Hematol; 2006 Nov; 34(11):1480-9. PubMed ID: 17046567
[TBL] [Abstract][Full Text] [Related]
6. PI3K-δ inhibition using CAL-101 exerts apoptotic effects and increases doxorubicin-induced cell death in pre-B-acute lymphoblastic leukemia cells.
Safaroghli-Azar A; Bashash D; Sadreazami P; Momeny M; Ghaffari SH
Anticancer Drugs; 2017 Apr; 28(4):436-445. PubMed ID: 28125433
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor activity of PI3K-δ inhibitor in hematologic malignant cells: Shedding new light on resistance to Idelalisib.
Bashash D; Safaroghli-Azar A; Dadashi M; Safa M; Momeny M; Ghaffari SH
Int J Biochem Cell Biol; 2017 Apr; 85():149-158. PubMed ID: 28254430
[TBL] [Abstract][Full Text] [Related]
8. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.
Herman SE; Gordon AL; Wagner AJ; Heerema NA; Zhao W; Flynn JM; Jones J; Andritsos L; Puri KD; Lannutti BJ; Giese NA; Zhang X; Wei L; Byrd JC; Johnson AJ
Blood; 2010 Sep; 116(12):2078-88. PubMed ID: 20522708
[TBL] [Abstract][Full Text] [Related]
9. Effect of CAL-101, a PI3Kδ inhibitor, on ribosomal rna synthesis and cell proliferation in acute myeloid leukemia cells.
Nguyen LX; Sesay A; Mitchell BS
Blood Cancer J; 2014 Jul; 4(7):e228. PubMed ID: 25014775
[No Abstract] [Full Text] [Related]
10. PI3K Abrogation Using Pan-PI3K Inhibitor BKM120 Gives Rise to a Significant Anticancer Effect on AML-Derived KG-1 Cells by Inducing Apoptosis and G2/M Arrest.
Sadeghi S; Esmaeili S; Pourbagheri-Sigaroodi A; Safaroghli-Azar A; Bashash D
Turk J Haematol; 2020 Aug; 37(3):167-176. PubMed ID: 32160736
[TBL] [Abstract][Full Text] [Related]
11. Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance.
Safaroghli-Azar A; Bashash D; Kazemi A; Pourbagheri-Sigaroodi A; Momeny M
Eur J Pharmacol; 2019 Jan; 842():89-98. PubMed ID: 30401630
[TBL] [Abstract][Full Text] [Related]
12. Synergistic in-vitro effects of combining an antiglycolytic, 3-bromopyruvate, and a bromodomain-4 inhibitor on U937 myeloid leukemia cells.
Kapp N; Stander XX; Stander BA
Anticancer Drugs; 2018 Jun; 29(5):429-439. PubMed ID: 29561307
[TBL] [Abstract][Full Text] [Related]
13. C-Myc inhibition sensitizes pre-B ALL cells to the anti-tumor effect of vincristine by altering apoptosis and autophagy: Proposing a probable mechanism of action for 10058-F4.
Sheikh-Zeineddini N; Safaroghli-Azar A; Salari S; Bashash D
Eur J Pharmacol; 2020 Mar; 870():172821. PubMed ID: 31770526
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of c-Myc overcomes cytotoxic drug resistance in acute myeloid leukemia cells by promoting differentiation.
Pan XN; Chen JJ; Wang LX; Xiao RZ; Liu LL; Fang ZG; Liu Q; Long ZJ; Lin DJ
PLoS One; 2014; 9(8):e105381. PubMed ID: 25127121
[TBL] [Abstract][Full Text] [Related]
15. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.
Leu WJ; Swain ShP; Chan SH; Hsu JL; Liu SP; Chan ML; Yu CC; Hsu LC; Chou YL; Chang WL; Hou DR; Guh JH
Oncotarget; 2016 Nov; 7(47):76995-77009. PubMed ID: 27769069
[TBL] [Abstract][Full Text] [Related]
16. NF-κB-dependent Mechanism of Action of c-Myc Inhibitor 10058-F4: Highlighting a Promising Effect of c-Myc Inhibition in Leukemia Cells, Irrespective of p53 Status.
Sayyadi M; Safaroghli-Azar A; Safa M; Abolghasemi H; Momeny M; Bashash D
Iran J Pharm Res; 2020; 19(1):153-165. PubMed ID: 32922477
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of PI3Kδ and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia.
He Y; Sun L; Xu Y; Fu L; Li Y; Bao X; Fu H; Xie C; Lou L
Cancer Lett; 2018 Apr; 420():49-59. PubMed ID: 29409989
[TBL] [Abstract][Full Text] [Related]
18. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies.
Castillo JJ; Furman M; Winer ES
Expert Opin Investig Drugs; 2012 Jan; 21(1):15-22. PubMed ID: 22112004
[TBL] [Abstract][Full Text] [Related]
19. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.
Lannutti BJ; Meadows SA; Herman SE; Kashishian A; Steiner B; Johnson AJ; Byrd JC; Tyner JW; Loriaux MM; Deininger M; Druker BJ; Puri KD; Ulrich RG; Giese NA
Blood; 2011 Jan; 117(2):591-4. PubMed ID: 20959606
[TBL] [Abstract][Full Text] [Related]
20. Idelalisib induces PUMA-dependent apoptosis in colon cancer cells.
Yang S; Zhu Z; Zhang X; Zhang N; Yao Z
Oncotarget; 2017 Jan; 8(4):6102-6113. PubMed ID: 28008149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
